I appreciate your thoughts Hawk, you make some good points. I am trying to load up some more in 2014, but I'm at a cross road. On one hand I dont want to wait too long and miss out on more upside through an M&A deal or partner. On the other hand dont want my extra shares to get shorted down if mngmt decides to do a 2nd cash raise and have a repeat of 3rd/4th quarter of this year. No way of knowing I guess... either way the product is going to be best in class and if I have to wait longer and ride it till 15+ then I am willing. fundamentals are strong and you cant ask for more in a late stage Bio company.Patience will definitely be rewarded with this winner. GLTAL
Sorry if I left anyone out, I dont post much but this latest price action got me to thinking. Is this alot of profit taking for year end? We know the catalysts that are coming but are still 3 months away or so, which leads me to my main question so I thought I would share and get your guys' feedback.
When CIC ph2 was completed in December 2012, Topline data was released a week therafter. So why such a long wait for the PH2 IBS-C Topline data? I am just wondering if this is a strategic play by SGYP to use this catalyst as momentum for a 2nd cash raise if they do not sell or partner by then. Im sure there are possibly many other reasons which is what I hope to gain from this post . Ofcourse my/our hope is for a buyout partner but we can not ignore this possiblity. Does anyone have an idea or thought on why the topline data will be announced in early Q2?